scholarly journals MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type

Oncotarget ◽  
2014 ◽  
Vol 5 (17) ◽  
pp. 7902-7916 ◽  
Author(s):  
Jiayu Li ◽  
Xuefei Li ◽  
Shengxiang Ren ◽  
Xiaoxia Chen ◽  
Yishi Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Wild Type ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Egfr Tkis

scholarly journals Plasma RANTES, IL-10, and IL-8 levels in non–small-cell lung cancer patients treated with EGFR-TKIs

2013 ◽  
Vol 6 (1) ◽  
pp. 139 ◽  
Author(s):  
Kanako Umekawa ◽  
Tatsuo Kimura ◽  
Shinzoh Kudoh ◽  
Tomohiro Suzumura ◽  
Takako Oka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Egfr Tkis

scholarly journals Efficacy of Paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e7767
Author(s):  
Yen-Han Tseng ◽  
Jen-Fu Shih ◽  
Heng-Sheng Chao ◽  
Yuh-Min Chen
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Small Cell ◽  
Wild Type ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Line Chemotherapy

Background Later line chemotherapy (≥2nd lines) such as Docetaxel or immunotherapy is frequently used. As the life expectancy of lung cancer patients is getting longer, we need to provide more treatment options. Other treatment options are not well documented except for Doxetaxel and immunotherapy. Therefore, the efficacy of paclitaxel plus TS1 (TTS1) is warranted. Methods We retrospectively reviewed the chart records of our non-small cell lung cancer patients who were treated between 2010 and 2013. Clinical characteristics, type of tumor, EGFR mutation status, and treatment response to first-line EGFR-TKI therapy and efficacy of TTS1, were collected. Results Twenty eight patients were enrolled in this study. No patients archived complete response and seven patients had partial response (ORR: 25%). The disease control rate was 60.7% (17/28). The progression free survival (PFS) was 4.0 months and overall survival (OS) was 15.8 months. Of them, 17 had EGFR mutations, eight EGFR wild type, and three were unknown EGFR status. After TTS1 treatment, patients with EGFR mutations had better PFS (4.9 months vs. 1.8 months) and OS (15.5 months vs. 7.2 months) compared with those of EGFR wild type. Conclusions TTS1 are effective later line chemotherapy, especially in tumor EGFR mutated patients. Paclitaxel plus TS1 is another treatment of choice for NSCLC patients before a more effective treatment strategy is found.

Current and Future Approaches in the Management of Non–Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs

2015 ◽  
Vol 16 (4) ◽  
pp. 252-261 ◽  
Author(s):  
Alexios Matikas ◽  
Dimitrios Mistriotis ◽  
Vassilis Georgoulias ◽  
Athanasios Kotsakis
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Egfr Tkis

scholarly journals Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis

2016 ◽  
Vol 5 (6) ◽  
pp. 1055-1065 ◽  
Author(s):  
Tao Jiang ◽  
Weijie Min ◽  
Yanan Li ◽  
Zhijian Yue ◽  
Chunyan Wu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Egfr Tkis
Sign in / Sign up

Export Citation Format

Share Document